tag payment-models 
Pharmaceutical Technology
MAY 1, 2023
CTH-004 is developed by genetically altering patient T cells for inserting a chimeric antigen receptor (CAR) to target a marker (TAG-72) on ovarian cancer cells and delete genes which are involved in T cell function suppression. In animal models of ovarian cancer, it demonstrated promising results.
Pharma Marketing Network
JUNE 8, 2020
I mean, you know, there has obviously been a lot of breakthrough biologics and different therapeutics like around cancers and things like that, that have high price tags because maybe they don’t have as big a market as you know, something’s wrong, you know blood pressure medication. So yeah, there is plenty to talk about there.
Expert insights. Personalized for you.
52 
Let's personalize your content